# Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

> **NCT06424717** · PHASE2 · WITHDRAWN · sponsor: **EMD Serono Research & Development Institute, Inc.**

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab
- **DRUG:** Tuvusertib

## Key facts

- **NCT ID:** NCT06424717
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-16
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-01-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial withdrawn based on re-prioritization of the clinical development path for tuvusertib. No subjects were enrolled.
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06424717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06424717, "Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06424717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*